Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review)

Lehrer,Steven

doi:10.3892/wasj.2020.42

Inhaled biguanides and mTOR inhibition for influenza and coronavirus (Review)

Authors:
- Steven Lehrer
View Affiliations

Affiliations: Fermata Pharma Inc., New York, NY 10023-7909, USA
Published online on: March 29, 2020 https://doi.org/10.3892/wasj.2020.42
Article Number: 1
Copyright: © Lehrer . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The mammalian target of rapamycin (mTOR) signaling pathway senses and responds to nutrient availability, energy sufficiency, stress, hormones and mitogens to modulate protein synthesis. Rapamycin is a bacterial product that can inhibit mTOR via the PI3K/AKT/mTOR pathway. mTOR signaling is necessary for the development of influenza and modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. In one human study, it was found that the treatment of severe H1N1 influenza-related pneumonia with rapamycin and steroids improved the outcome. However, in other studies, immunosuppression with systemic steroids, and possibly rapamycin as well, was associated with an increased morbidity/mortality and a prolonged viral replication. In order to avoid the systemic side-effects, some investigators have postulated that the inhalation of rapamycin would be desirable. However, the inhalation of rapamycin, with its well-documented lung toxicity, could be contraindicated. Another class of drug, biguanides, can also inhibit mTOR, but have no lung toxicity. Biguanides are widely used small molecule drugs prescribed as oral anti-diabetics that have exhibited considerable promise in oncology. During the 1971 outbreak of influenza, diabetic patients treated with the biguanides, phenformin and buformin, had a lower incidence of infection than diabetics treated with sulfonylureas or insulin. Both buformin and phenformin reduce the mortality of influenza in mice; phenformin is less effective than buformin. The inhalation of buformin or phenformin for influenza may be an effective novel treatment strategy that would limit the risk of systemic side-effects associated with biguanides due to the low inhaled dose. Coronavirus disease 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019-2020 coronavirus outbreak. It is primarily spread between individuals via small droplets emitted from infected individuals when breathing or coughing. PI3K/AKT/mTOR signaling responses play important roles in MERS-CoV infection and may represent a novel drug target for therapeutic intervention strategies. The present review article discusses the effects of biguanides on influenza and coronavirus.

View Figures

View References

1	Doyle JD, Chung JR, Kim SS, Gaglani M, Raiyani C, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, et al: Interim estimates of 2018-19 seasonal influenza vaccine effectiveness-United States, February 2019. MMWR Morb Mortal Wkly Rep. 68:135–139. 2019.PubMed/NCBI View Article : Google Scholar
2	Cohen J: Waning immunity. Science. 364:224–227. 2019.PubMed/NCBI View Article : Google Scholar
3	Moscona A: Neuraminidase inhibitors for influenza. N Engl J Med. 353:1363–1373. 2005.PubMed/NCBI View Article : Google Scholar
4	O'Hanlon R and Shaw ML: Baloxavir marboxil: The new influenza drug on the market. Curr Opin Virol. 35:14–18. 2019.PubMed/NCBI View Article : Google Scholar
5	Takashita E, Ichikawa M, Morita H, Ogawa R, Fujisaki S, Shirakura M, Miura H, Nakamura K, Kishida N, Kuwahara T, et al: Human-to-human transmission of influenza A(H3N2) virus with reduced susceptibility to baloxavir, Japan, February 2019. Emerg Infect Dis. 25:2108–2111. 2019.PubMed/NCBI View Article : Google Scholar
6	Ma XM and Blenis J: Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 10:307–318. 2009.PubMed/NCBI View Article : Google Scholar
7	Keating R, Hertz T, Wehenkel M, Harris TL, Edwards BA, McClaren JL, Brown SA, Surman S, Wilson ZS, Bradley P, et al: The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nat Immunol. 14:1266–1276. 2013.PubMed/NCBI View Article : Google Scholar
8	Nikolaidis NM, Noel JG, Pitstick LB, Gardner JC, Uehara Y, Wu H, Saito A, Lewnard KE, Liu H, White MR, et al: Mitogenic stimulation accelerates influenza-induced mortality by increasing susceptibility of alveolar type II cells to infection. Proc Natl Acad Sci USA. 114:E6613–E6622. 2017.PubMed/NCBI View Article : Google Scholar
9	Wang CH, Chung FT, Lin SM, Huang SY, Chou CL, Lee KY, Lin TY and Kuo HP: Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure. Crit Care Med. 42:313–321. 2014.PubMed/NCBI View Article : Google Scholar
10	Chuang YC, Ruan SY and Huang CT: Compelling results of adjuvant therapy with sirolimus for severe H1N1 pneumonia. Crit Care Med. 42:e687–e688. 2014.PubMed/NCBI View Article : Google Scholar
11	Ison MG: Adjuvant immunosuppression in the management of severe influenza: Friend or foe? Crit Care Med. 42:457–459. 2014.PubMed/NCBI View Article : Google Scholar
12	Gupta A, Pant G, Mitra K, Madan J, Chourasia MK and Misra A: Inhalable particles containing rapamycin for induction of autophagy in macrophages infected with Mycobacterium tuberculosis. Mol Pharm. 11:1201–1207. 2014.PubMed/NCBI View Article : Google Scholar
13	Carvalho SR, Watts AB, Peters JI, Liu S, Hengsawas S, Escotet-Espinoza MS and Williams RO III: Characterization and pharmacokinetic analysis of crystalline versus amorphous rapamycin dry powder via pulmonary administration in rats. Eur J Pharm Biopharm. 88:136–147. 2014.PubMed/NCBI View Article : Google Scholar
14	Weiner SM, Sellin L, Vonend O, Schenker P, Buchner NJ, Flecken M, Viebahn R and Rump LC: Pneumonitis associated with sirolimus: Clinical characteristics, risk factors and outcome-a single-centre experience and review of the literature. Nephrol Dial Transplant. 22:3631–3637. 2007.PubMed/NCBI View Article : Google Scholar
15	Clements A, Gao B, Yeap SH, Wong MK, Ali SS and Gurney H: Metformin in prostate cancer: Two for the price of one. Ann Oncol. 22:2556–2560. 2011.PubMed/NCBI View Article : Google Scholar
16	Pollak M: Potential applications for biguanides in oncology. J Clin Invest. 123:3693–3700. 2013.PubMed/NCBI View Article : Google Scholar
17	Lehrer S, Rheinstein P and Mulshine J: Inhaled buformin for lymphangioleiomyomatosis and early (airway confined) lung cancer. American Association for Cancer Research Annual Meeting Abstracts: 14.A.638.AACR, 2014.
18	Babinski S and Giermaziak H: Influenza epidemic in 1971 in diabetics treated with 1-butyl-biguanidine hydrochloride (Silubin retard) and 1-phenylethyl-biguanidine hydrochloride (Phenformin). Pol Tyg Lek. 28:1815–1817. 1973.(In Polish). PubMed/NCBI
19	Pinto F, Maillard JY, Denyer SP and McGeechan P: Polyhexamethylene biguanide exposure leads to viral aggregation. J Appl Microbiol. 108:1880–1888. 2010.PubMed/NCBI View Article : Google Scholar
20	Thakkar N, Pirrone V, Passic S, Keogan S, Zhu W, Kholodovych V, Welsh W, Rando R, Labib M, Wigdahl B and Krebs FC: Persistent interactions between biguanide-based compound NB325 and CXCR4 result in prolonged inhibition of human immunodeficiency virus type 1 infection. Antimicrob Agents Chemother. 54:1965–1972. 2010.PubMed/NCBI View Article : Google Scholar
21	Denys A and Bocian J: Effect of Silubin-retard (1-butyl-biguanide hydrochloride) on the course of influenza-virus infection in mice. Pol Tyg Lek. 25:332–334. 1970.(In Polish). PubMed/NCBI
22	Orthel FW: Influenza virus titrations and the inhibitor of hemagglutination in normal allantoic fluid. Arch Gesamte Virusforsch. 38:347–356. 1972.PubMed/NCBI View Article : Google Scholar
23	Bocian J, Denys A and Czernek Z: Effect of biguanidine derivatives phenformin and buformin on course of infection with influenza virus in mouse. Dissertationes Pharmaceuticae et Pharmacologicae. 23(581)1971.
24	Fukao K, Noshi T, Yamamoto A, Kitano M, Ando Y, Noda T, Baba K, Matsumoto K, Higuchi N, Ikeda M, et al: Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection. J Antimicrob Chemother. 74:654–662. 2019.PubMed/NCBI View Article : Google Scholar
25	Luft D, Schmülling RM and Eggstein M: Lactic acidosis in biguanide-treated diabetics: A review of 330 cases. Diabetologia. 14:75–87. 1978.PubMed/NCBI View Article : Google Scholar
26	Garcia Rubino ME, Carrillo E, Ruiz Alcala G, Dominguez-Martin A, A Marchal J and Boulaiz H: Phenformin as an anticancer agent: Challenges and prospects. Int J Mol Sci. 20(E3316)2019.PubMed/NCBI View Article : Google Scholar
27	Garcia EY: Flumamine, a new synthetic analgesic and anti-flu drug. J Philipp Med Assoc. 26:287–293. 1950.PubMed/NCBI
28	Bailey CJ: Metformin: Historical overview. Diabetologia. 60:1566–1576. 2017.PubMed/NCBI View Article : Google Scholar
29	Patton JS, Fishburn CS and Weers JG: The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 1:338–344. 2004.PubMed/NCBI View Article : Google Scholar
30	Kindrachuk J, Ork B, Hart BJ, Mazur S, Holbrook MR, Frieman MB, Traynor D, Johnson RF, Dyall J, Kuhn JH, et al: Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Chemother. 59:1088–1099. 2015.PubMed/NCBI View Article : Google Scholar
31	Pizzorno A, Padey B, Terrier O and Rosa-Calatrava M: Drug repurposing approaches for the treatment of influenza viral infection: Reviving old drugs to fight against a long-lived enemy. Front Immunol. 10(531)2019.PubMed/NCBI View Article : Google Scholar